Although adding molecular characteristics into the histological diagnosis of glioblastoma is beneficial for precise diagnosis, single-gene tests based on DNA methylation analysis like MGMT methylation status, fluorescence in situ hybridization [1p/19q codeletion, EGFR, proto-oncogene C-Myc (MYC), class E basic helix-loop-helix protein 37 (MYCN), platelet derived growth factor receptor alpha (PDGFRA) and 19q13.42), or immunohistochemistry (catenin beta-1 (CTNNB1) and Lin-28 homolog A (LIN28A)], have proven difficult to be standardized (128). This evidence concerns the gene CTNNB1 and glioblastoma.